PDF(Pubmed)
Abstract：
Diffuse Large B-cell Lymphoma (DLBCL), with its intrinsic genetic and epigenetic heterogeneity, exhibits significantly variable clinical outcomes among patients treated with the current standard regimen. Disulfidptosis, a novel form of regulatory cell death triggered by disulfide stress, is characterized by the collapse of cytoskeleton proteins and F-actin due to intracellular accumulation of disulfides. We investigated the expression variations of disulfidptosis-related genes (DRGs) in DLBCL using two publicly available gene expression datasets. The initial analysis of DRGs in DLBCL (GSE12453) revealed differences in gene expression patterns between various normal B cells and DLBCL. Subsequent analysis (GSE31312) identified DRGs strongly associated with prognostic outcomes, revealing eight characteristic DRGs (CAPZB, DSTN, GYS1, IQGAP1, MYH9, NDUFA11, NDUFS1, OXSM). Based on these DRGs, DLBCL patients were stratified into three groups, indicating that (1) DRGs can predict prognosis, and (2) DRGs can help identify novel therapeutic candidates. This study underscores the significant role of DRGs in various biological processes within DLBCL. Assessing the risk scores of individual DRGs allows for more precise stratification of prognosis and treatment strategies for DLBCL patients, thereby enhancing the effectiveness of clinical practice.
摘要：
弥漫性大B细胞淋巴瘤(DLBCL),具有内在的遗传和表观遗传异质性，在使用当前标准方案治疗的患者中，临床结局显着变化。二硫化物下垂，一种由二硫键应激引发的新型调节性细胞死亡，其特征是由于二硫化物的细胞内积累而导致细胞骨架蛋白和F-肌动蛋白崩溃。我们使用两个公开可用的基因表达数据集研究了DLBCL中二硫凋亡相关基因（DRG）的表达变化。DLBCL（GSE12453）中DRG的初步分析揭示了各种正常B细胞和DLBCL之间基因表达模式的差异。后续分析(GSE31312)确定了与预后结果密切相关的DRGs，揭示了八个特征DRG(CAPZB，DSTN,GYS1，IQGAP1，MYH9，NDUFA11，NDUFS1，OXSM）。基于这些DRG，DLBCL患者分为三组，表明(1)DRGs可以预测预后，和(2)DRGs可以帮助识别新的治疗候选物。这项研究强调了DRGs在DLBCL中各种生物过程中的重要作用。评估个体DRG的风险评分可以更精确地对DLBCL患者的预后和治疗策略进行分层。从而提高临床实践的有效性。
